TY - JOUR
T1 - Biological Therapies of Immunologic Diseases
T2 - Strategies for Immunologic Interventions
AU - Polk, Brooke I.
AU - Rosenwasser, Lanny J.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - The immune system possesses a vast number of potential targets for therapeutic intervention. Although therapies for many pathways have been pursued, only few have yielded significant success. Hindrances in altering biologic pathways include the potential for unwanted downstream effects, ineffectiveness owing to biological redundancy, recognition of a therapeutic molecule as foreign by the body's innate immune system, and the risks of subsequent malignancy and/or autoimmunity. This article covers currently available biotherapeutic agent classes as well as potential direction for future therapy.
AB - The immune system possesses a vast number of potential targets for therapeutic intervention. Although therapies for many pathways have been pursued, only few have yielded significant success. Hindrances in altering biologic pathways include the potential for unwanted downstream effects, ineffectiveness owing to biological redundancy, recognition of a therapeutic molecule as foreign by the body's innate immune system, and the risks of subsequent malignancy and/or autoimmunity. This article covers currently available biotherapeutic agent classes as well as potential direction for future therapy.
KW - Biotherapeutic
KW - Biotherapy
KW - Immunomodulatory
KW - Monoclonal antibody
UR - http://www.scopus.com/inward/record.url?scp=85014073809&partnerID=8YFLogxK
U2 - 10.1016/j.iac.2017.01.003
DO - 10.1016/j.iac.2017.01.003
M3 - Review article
C2 - 28366475
AN - SCOPUS:85014073809
SN - 0889-8561
VL - 37
SP - 247
EP - 259
JO - Immunology and Allergy Clinics of North America
JF - Immunology and Allergy Clinics of North America
IS - 2
ER -